Eli Lilly and Company LLY Chief Executive

What David A. Ricks says in public, and what their own SEC filings show they own.

David A. Ricks

David A. Ricks

Chair & CEO · Eli Lilly and Company

CEO since 2017. 25+ year Lilly veteran. Led operations in Canada and China, ran Lilly USA and Bio-Medicines. Purdue BS, Indiana MBA.

What they own

Ownership

Skin in the game
16/ 70
Level 1Steward

Ricks owns about 0% of Eli Lilly and Company, worth $820.1M at the last close.

SEC filings
65
Stake 708,781 reported shares ≈ 0.1% of shares outstanding — no 13G on file, so an estimate 4/35
Founder Not assessed — whether they founded the company has not been researched Not assessed
Tenure No start date on record, so tenure scores nothing 0/10
Track record Not assessed — their prior companies have not been researched Not assessed
Direction No open-market buys or sales in the last year 5/15
Discipline 2 late Form 4s in 65 filings 7/10

Nobody has researched this person's career yet, so founder and track record are left out of the score and of the total above.

Score = stake band (35) + founder (15) + tenure (10) + track record (15) + 12-month direction (−10…15) + filing discipline (10). An axis we have not researched is left out of the score and of the total it is shown over. Every input links to a filing or to our own research; the bands are ours.

Reported · Forms 3, 4, 5 708,781 Every lot on the person's own filings, as of Feb 9, 2026
Paper trail 2 late filings Form 4 covering a 2023-02-08 gift in ELI LILLY & Co was filed 2023-02-14, 4 business days later; Section 16 allows two.
Reported Eli Lilly and Company shares Forms 3, 4 and 5 · as of 2026-02-09
0200K400K600K800K 20122013201420152016201720182019202020212022202320242025 Feb 2026: net +56,551 shares across 3 movements (largest: award +38,913)Nov 2025: net −24,740 shares across 1 movement (largest: gift −24,750) 708,781

Dots mark the months the activity below moved the line. Hover one for that month's net move, how many movements it folds and the largest.

How the stake is held
SecurityHeld viaShares
Common StockDirect571,715
Common StockDavid A. Ricks SLAT68,656
Common StockDavid A. Ricks 2022 GRAT54,117
Common Stock401(k)7,307
Common StockDavid A. Ricks 2025 GRAT6,685
Common StockTrust300
Reported as of 2026-02-09708,781
Held directly
81%
Vehicles
5 trusts or entities
Last filing
Feb 11, 2026
Activity · last 12 months 4 events folded from 4 filing lines · Every filing on EDGAR ↗
DateTypeWhat happenedSharesPriceValueNote
Feb 9, 2026 Award Grant or award +38,913 $1,044.69 $40.7M
Feb 1, 2026 Exercise Option or RSU conversion +31,932 — —
Feb 1, 2026 Tax Shares withheld for tax −14,296 $1,037.20 $14.8M
Nov 10, 2025 Gift Gift −24,750 — —
Every issuer David A. Ricks files as an insider of
CompanyRoleReportedBeneficial% of class
LLY ELI LILLY & Co This page President, Chair, and CEO 708,781
2026-02-09		 — —
ADBE ADOBE INC. Director 20,430
2026-06-25		 — —

Reported is every lot on the person's own Forms 3, 4 and 5 — direct and through trusts. Beneficial is the figure stated on the latest Schedule 13D/G cover page, which can exclude shares the person disclaims and include options exercisable within 60 days, so the two are never added together.

Paper trail

65 filings under CIK 0001538604 · captured 2026-09-05 · All filings on EDGAR ↗

On the record with shareholders

Earnings calls

  1. Q2 2026 Aug 5, 2026 Ricks argued that Lilly's quarter was a portfolio story rather than an obesity story alone — revenue up 48%, but with oncology, immunology and neuroscience medicines up 121% together — and that the constraint on the obesity franchise is access rather than demand, pointing to the Medicare GLP-1 Bridge programme that opened $50-a-month coverage to 20 million eligible Americans on 1 July and lifted covered lives by 35%. He closed the prepared remarks with "we're not satisfied." In Q&A he spent his time on retatrutide: Lilly wants to file it as a biologic, that position is in active litigation after a mixed first court decision, the clinical package is complete and only chemistry-and-manufacturing work remains, and the submission is still targeted for the first quarter of 2027. Read the call · 5 quotes →
In their own words

Podcasts, interviews & articles

9 recorded appearances

2026

2025

Who else runs a company like this one

Every CEO we track →
Andrew Dudum Hims & Hers Health, Inc. (HIMS) Joaquin Duato Joaquin Duato Johnson & Johnson (JNJ) Robert A. Michael AbbVie Inc. (ABBV) Stephen J. Hemsley Stephen J. Hemsley UnitedHealth Group Incorporated (UNH)